A two-stage therapeutic design in the spontaneous AKR lymphoma system.
D000577:Amides / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001374:Azacitidine / Q000627:therapeutic use; D003498:Cyclic P-Oxides / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004195:Disease Models, Animal; D004338:Drug Combinations; D005260:Female; D007093:Imidazoles / Q000627:therapeutic use; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008815:Mice, Inbred Strains; D010078:Oxazines / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage* / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013997:Time Factors; D014226:Triazenes / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage* / Q000627:therapeutic use
D000577:Amides; D000970:Antineoplastic Agents; D003498:Cyclic P-Oxides; D004338:Drug Combinations; D007093:Imidazoles; D010078:Oxazines; D014226:Triazenes; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001374:Azacitidine; D011241:Prednisone; D008727:Methotrexate